Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2021 16:01 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Third Quarter 2021 Financial Results and Recent Corporate Developments

Net product sales for the third quarter of 2021 reached $166.9 million, a 37% increase over the same quarter of prior yearIn light of its continued over-performance, Sarepta raises its full-year...
November 02, 2021 16:30 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will...
October 29, 2021 18:15 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on October 29, 2021...
October 27, 2021 08:30 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Developments on November 3, 2021

CAMBRIDGE, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2021 financial...
October 13, 2021 21:15 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock

CAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has priced an...
October 12, 2021 16:04 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Preliminary Financial Results for the Third Quarter Ended September 30, 2021

CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced preliminary financial...
October 12, 2021 16:01 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock

CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (Nasdaq:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it is offering to sell,...
October 11, 2021 09:13 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics’ SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne

Results presented at ‘Micro-dystrophin Day’ highlight breadth, depth and strength of the clinical evidence to date for SRP-9001 in treating Duchenne muscular dystrophy; tolerability profile remains...
October 04, 2021 16:30 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Opens Genetic Therapies Center of Excellence in Columbus, Ohio

Center dedicated to research and development activities to advance Sarepta’s industry-leading, multi-platform pipelineThe Center encompasses 85,000 square feet of space, tripling Sarepta’s footprint...
October 04, 2021 07:00 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Initiation of EMBARK, a Global Pivotal Study of SRP-9001, a Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

- Sarepta to host “SRP-9001 Micro-dystrophin R&D Day” at 8:30 a.m. Eastern Time on Monday, Oct. 11, 2021 CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc....

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right